NCT00277823View on ClinicalTrials.gov

Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL

Enrollment

480

Participants

Timeline

Start Date

February 28, 2006

Study Completion Date

January 31, 2007

Conditions

Major Depressive Disorder

Interventions

DRUG

DVS-SR 50 mg

DRUG

DVS-SR 100 mg

DRUG

Placebo

Trial Locations (25)

10021

New York

10024

New York

20037

Washington D.C.

29201

Columbia

29407

Charleston

30060

Marietta

30080

Smyrna

33173

Miami

33702

St. Petersburg

43623

Toledo

45408

Dayton

48336

Farmington Hills

53223

Brown Deer

60048

Libertyville

70115

New Orleans

73103

Oklahoma City

84107

Salt Lake City

90210

Beverly Hills

91324

Northridge

97210

Portland

06030

Farmington

08021

Clementon

08057

Moorestown

Unknown

Philadelphia

Seattle

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00277823 - Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter